The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
ApexOnco Front Page
Recent articles
The depressed company could use Mylotarg as a stepping stone in AML.
After Niagara the company faces three pivotal catalysts; none is a slam-dunk.
The group eyes a broader use than Immunocore’s Kimmtrak.
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
A macrocycle-based therapy enters the clinic, as do projects targeting p53 interaction and IL-12.
The NMPA has refused to back PFS, plus subgroup OS analyses, in fruquintinib’s stomach cancer study.
Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.
